ACCESS Newswire
10 Sep 2019, 17:31 GMT+10
REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products in Hong Kong. Avinger has an exclusive distribution agreement with Integmed Ltd. for the sale and marketing of Avinger's Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO) crossing systems in Hong Kong. The first shipment of devices has been made under the agreement and training of Integmed's sales and clinical support teams has been completed.
Dr. Yiu Che Chan, a highly-experienced vascular surgeon and a clinical associate professor at The University of Hong Kong, performed the first four cases using Lumivascular technology in Hong Kong at Queen Mary Hospital. Dr. Chan used Ocelot to cross a challenging CTO in one patient and successfully treated lesions in three additional patients with Avinger's Pantheris image-guided atherectomy catheter. Prior to conducting the first cases in Hong Kong, Dr. Chan observed cases and received training from Dr. Arne Schwindt, a vascular surgeon and leading Lumivascular operator, at St. Franziskus Hospital in Münster, Germany.
Following his initial experience with Lumivascular technology, Dr. Chan commented, "I was impressed by how easy Pantheris was to use in my first cases and how efficiently we were able to remove plaque to restore blood flow. The imaging provided by Ocelot and Pantheris enabled me to effectively target the disease, while minimizing vascular injury during treatment, which I believe will lead to better long-term outcomes for my patients."
"We are excited to expand our presence in the Asia Pacific region through our commercial launch in Hong Kong and partnership with Integmed," said Jeff Soinski, Avinger's President and CEO. "We appreciate Dr. Chan's pioneering efforts with Lumivascular technology in Hong Kong and are happy he delivered such positive results for his patients."
Lumivascular technology allows physicians, for the first time ever, to see the inside of the artery during an atherectomy or CTO crossing procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger's proprietary Lightbox console. Physicians performing atherectomy or crossing CTOs with other devices must rely solely on X-ray images, as well as tactile feedback, to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Public Relations Contact:
Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7942
[email protected]
Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
[email protected]
SOURCE: Avinger, Inc.
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationNEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...
Argentinian composer Lalo Schifrin, the genre-blending film and television composer behind the Mission: Impossible, Bullitt, and Cool...